BioLineRx Ltd. Q2 2025 Earnings Recap

BLRX Q2 2025 August 14, 2025

Get alerts when BLRX reports next quarter

BioLineRx reported promising advancements in pipeline expansion, highlighted by significant results from ongoing trials, including its FDA-approved drug, APHEXDA. The company seeks to enhance its oncology and rare disease portfolio through strategic acquisitions, bolstered by successful clinical data from recent studies.

Earnings Per Share Miss

$-1.00 vs $-0.35 est.

-185.7% surprise

Revenue Miss

304000 vs 776670 est.

-60.9% surprise

Market Reaction

1-Day -1.59%

5-Day -4.77%

30-Day +3.18%

See BLRX alongside your other holdings

Add to your portfolio — free

Key Takeaways

APHEXDA's successful FDA approval in September 2023 positions BioLineRx strategically in the multiple myeloma treatment landscape, supported by a lucrative commercialization agreement with Ayrmid Pharma.
Ongoing Phase IIb trials for motixafortide in pancreatic cancer show a 64% partial response rate, significantly surpassing historical averages, indicating strong clinical potential.
The company is focused on acquiring early-stage assets in oncology and rare diseases, with expectations of a definitive transaction announcement later this year.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BLRX on AllInvestView.

Next Q3 2025